PATENT CLAIM ANALYSIS

Application Number: 16003513
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["544", "360000"]

Abstract:
The present invention provides crystalline forms of the chloride monohydrochloride salt of fosnetupitant, methods of making the crystalline forms, and pharmaceutical dosage forms that make use of the crystalline forms.

Claim (Index 39):
Amorphous (4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methylpiperazin-1-ium-1-yl)methyl hydrogen phosphate (fosnetupitant) chloride hydrochloride.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 94.0
- Lexical Diversity: 1.5
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15282016', '13223023', '15696616', '15589087', '14478627']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7170842513223052
- 35 USC 102 Novelty (BERT): 0.5400480552210922
- Combined Prediction Score: 0.6993806317121839
- Mean Citation Score: 253.77362
- Max Citation Score: 370.36542
- Similarity Product: 327.7420459589195

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test